Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Longeveron Inc
(NQ:
LGVN
)
2.060
+0.060 (+3.00%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Longeveron Inc
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
This Company Is On a Mission to Level the Playing Field for Retail Investors
January 06, 2022
Image provided by BlackBoxStocks The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Why Longeveron Shares Are Rising Today
January 05, 2022
Longeveron Inc (NASDAQ: LGVN) is trading higher Wednesday after the company announced initiation of the Phase 2a clinical trial of lomecel-B for the treatment of Alzheimer...
Via
Benzinga
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
January 05, 2022
Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Exclusive: Longeveron Kickstarts Its Mid-Stage Alzheimer's Disease Trial
January 05, 2022
Longeveron Inc (NASDAQ: LGVN) has initiated its Phase 2a clinical trial evaluating Lomecel-B for Alzheimer’s disease (AD). The first patient has consented to...
Via
Benzinga
25 Stocks Moving In Tuesday's Mid-Day Session
December 28, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 64.6% to $18.99 as traders circulated a social media post on a potential short squeeze. Flotek Industries, Inc. (NYSE...
Via
Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
December 23, 2021
Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) jumped 37.3% to $2.0182. Pasithea recently said it expanded its footprint with second Ketamine Therapy Clinic in the UK....
Via
Benzinga
54 Biggest Movers From Thursday
December 27, 2021
Gainers 22nd Century Group, Inc. (NASDAQ: XXII) surged 38.6% to settle at $3.05. The FDA authorized marketing of tobacco products that help reduce exposure to and consumption of...
Via
Benzinga
5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again
December 20, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NY...
Via
Benzinga
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
December 17, 2021
Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates!
Via
InvestorPlace
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
December 21, 2021
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to...
Via
FinancialNewsMedia
Exposures
Product Safety
Longeveron Inc. (NASDAQ:LGVN) Long Term Investor Notice: Investigation of Potential Wrongdoing
December 17, 2021
San Diego, CA -- (SBWIRE) -- 12/17/2021 -- An investigation on behalf of current long-term investors in shares of Longeveron Inc. (NASDAQ:LGVN) concerning potential breaches of fiduciary duties by...
Via
SBWire
5 Short Squeeze Candidates To Watch: Petros Pharma Tops List With 254% Cost To Borrow, One Of Highest Figures On Record
December 13, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC...
Via
Benzinga
3 Predictions for the Stock Market in 2022
December 10, 2021
Precisely predicting what the market will do is an easy way to get everything wrong, but here are three trends to look for in 2022.
Via
InvestorPlace
Why Longeveron’s Good News Isn’t Telling Us the Whole Truth
December 10, 2021
LGVN stock has soared in 2021 with the latest upbeat FDA news but a closer look at Longeveron's financials tells a different story.
Via
InvestorPlace
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
18 Stocks Moving in Friday's Pre-Market Session
December 10, 2021
Gainers Context Therapeutics Inc. (NASDAQ: CNTX) rose 48.6% to $9.30 in pre-market trading as the company announced data from ONA-XR in early breast cancer. The company said ONA-...
Via
Benzinga
Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low
December 09, 2021
Following the market opening Thursday, the Dow traded down 0.22% to 35,676.45 while the NASDAQ fell 0.30% to 15,740.38. The S&P also fell, dropping 0.21% to 4,691.18. The U.S...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Systemic Lupus Erythematosus Treatment Market Projected To Reach $3.56 Billion By 2027
December 08, 2021
Palm Beach, FL –December 8, 2021 – FinancialNewsMedia.com News Commentary – Systemic Lupus Erythematosus is also known as lupus. It is an autoimmune disease that affects all parts of your body. The...
Via
FinancialNewsMedia
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
December 07, 2021
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.
Via
InvestorPlace
Exposures
COVID-19
2 Big Stock Bets That Are Insiders Are Buying Now
December 06, 2021
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy.
Via
InvestorPlace
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
December 06, 2021
HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per year Orphan Drug Designation confers certain benefits and may result in...
Via
Benzinga
Exposures
Product Safety
Is Longeveron a Good Biotech Stock to Buy?
December 05, 2021
Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company.
Via
The Motley Fool
58 Biggest Movers From Friday
December 06, 2021
Gainers Hagerty, Inc. (NYSE: HGTY) shares jumped 46.5% to close at $15.62. TuanChe Limited (NASDAQ: TC) gained 44.7% to settle at $3.30. IO Biotech, Inc. (NASDAQ: IOBT) shares...
Via
Benzinga
Mid-Afternoon Market Update: DocuSign Drops Following Weak Revenue Forecast; Longeveron Shares Climb
December 03, 2021
Toward the end of trading Friday, the Dow traded down 0.37% to 34,512.05 while the NASDAQ fell 2.28% to 15,029.99. The S&P also fell, dropping 1.13% to 4,525.40. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Mid-Day Market Update: Nasdaq Dips Over 400 Points; Marvell Technology Shares Rise Following Upbeat Earnings
December 03, 2021
Midway through trading Friday, the Dow traded down 0.77% to 34,373.98 while the NASDAQ fell 2.8% to 14,950.19. The S&P also fell, dropping 1.52% to 4,507.37. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
41 Stocks Moving In Friday's Mid-Day Session
December 03, 2021
Gainers IO Biotech, Inc. (NASDAQ: IOBT) jumped 42% to $11.74. The company, last month, priced its IPO at $14 per share. Celyad Oncology SA (NASDAQ: CYAD) shares jumped 38.7% to...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Mid-Morning Market Update: Markets Open Lower; Big Lots Issues Weak Profit Forecast
December 03, 2021
Following the market opening Friday, the Dow traded down 0.31% to 34,532.63 while the NASDAQ fell 1.44% to 15,160.41. The S&P also fell, dropping 0.60% to 4,549.65. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
December 03, 2021
Good morning, investor! We're at the end of the week and it starts off with the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Longeveron Shares Gain After Lead Product Gets FDA Orphan Drug Tag For Type Of Congenital Heart Defect
December 03, 2021
The FDA has granted Orphan Drug designation to Longeveron Inc's (NASDAQ: LGVN) lead investigational product Lomecel-B for Hypoplastic left heart syndrome (...
Via
Benzinga
Exposures
Product Safety
20 Stocks Moving in Friday's Pre-Market Session
December 03, 2021
Gainers BIOLASE, Inc. (NASDAQ: BIOL) rose 27.2% to $0.52 in pre-market trading. Biolase reporte in Form4 filing that President bought 70,000 shares at an average price of $0.45...
Via
Benzinga
61 Biggest Movers From Yesterday
December 02, 2021
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.